Alphamab Oncology (09966.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 7.87

From 52W high−49.45%

Volume1.30M

Market capHKD 7.45B

P/E (TTM)—

P/S (TTM)12.4x

Div yield—

Key dataSep 18, 2026

Open

HKD 7.87

From 52W high

−49.45%

Volume

1.30M

Market cap

HKD 7.45B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−39.8x

P/E (TTM)

—

RSI (14)

41.8

MomentumView details →

1D Return

+1.04%

YTD Return

−20.92%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−39.8x

EV/Sales

10.1x

P/S (TTM)

12.4x

P/B (TTM)

3.8x

ProfitabilityView details →

Gross Margin

76.09%

Net Margin

−33.79%

EBITDA Margin

−25.42%

ROE (TTM)

−10.39%

ROA (TTM)

−8.03%

Asset Turnover

0.24x

GrowthView details →

Revenue YoY

−34.57%

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

+48.97%

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

+1.04%

YTD Return

−20.92%

1Y Return

−34.04%

RSI (14)

41.8

vs 50D SMA

−3.73%

vs 200D SMA

−12.81%

Capital & dividendView details →

Debt/Equity

0.16x

Current Ratio

4.02x

Quick Ratio

3.68x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−HKD 0.05

EPS Surprise

89.36%

Beats (12Q)

1/12

Next Q EPS Est

−HKD 0.32

Avg Surprise (4Q)

89.36%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

1.30B

Net Income (TTM)

59.05M

Op. CF (TTM)

—

Next earningsMar 30, 2027 →

Latest newsMore news →

Alphamab Oncology announced a resolution to repurchase its own shares from the open market, with a maximum amount of 80 million HKD.21d ago

Alphamab Oncology (09966.HK) reported an interim net loss of 40.46 million RMB for the six months ended June 2026, compared with a net profit of 21.58 million RMB in the same period last year, with revenue down 15.1% year-on-year to 271 million RMB.24d ago

Similar companies

CStone Pharmaceuticals02616.HK Ionis Pharmaceuticals, Inc.IONS CARsgen Therapeutics Holdings Limited02171.HK 苑东生物688513.SH Alkermes plcALKS Immunovant, Inc.IMVT Find similar companies →

Latest newsMore news →

Alphamab Oncology announced a resolution to repurchase its own shares from the open market, with a maximum amount of 80 million HKD.21d ago Alphamab Oncology (09966.HK) reported an interim net loss of 40.46 million RMB for the six months ended June 2026, compared with a net profit of 21.58 million RMB in the same period last year, with revenue down 15.1% year-on-year to 271 million RMB.24d ago